ADAC Laboratories posted a 19% increase in revenues for its fourthquarter (end-October), the Milpitas, CA, company reported lastweek. Operating income was also higher, although net income wasaffected due to accounting changes related to the company's
ADAC Laboratories posted a 19% increase in revenues for its fourthquarter (end-October), the Milpitas, CA, company reported lastweek. Operating income was also higher, although net income wasaffected due to accounting changes related to the company's changein income-tax status.
ADAC's fourth-quarter revenues for the most recent period were$50.2 million, compared to $42.4 million in the same period of1994. Operating income increased 45% to $5.1 million, althoughyear-to-year net income comparisons are difficult because thevendor's net income in 1994 was impacted by one-time charges relatedto litigation with Elscint and credits due to an income tax benefit.
ADAC had net income of $2.8 million in the most recent quarter,compared to net income of $6.4 million in the same period lastyear. If last year's charges and credits were excluded and thevendor had been taxed in that quarter at this year's rate of 35%,ADAC would have had net income in 1994's fourth quarter of $2.2million. ADAC's tax rate changed from the low 20% range in 1994to 35% this year due to the expiration of tax credits relatedto losses the company experienced in the 1980s.
For the year, ADAC reported revenues of $184.8 million, up 5%compared to $176.3 million in sales in 1994. Net income for 1995was $11.1 million, compared to last year's net income of $17.5million. ADAC would have recorded net income for 1994 of $12.9million if tax credits and nonrecurring charges were excluded.
As previously reported, ADAC experienced a 33% gain in bookingsfor the quarter, to a company-record $64 million.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.